Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCTR | P47872 | 9/20 | 0.65 |
| ▸ | SMO | Q99835 | 1/20 | 0.65 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14075707 | 0.95 | SCTR (0.67) | SCTRSMOPDGFRAKDM4EMEN1 | |
| SCHEMBL14075692 | 0.88 | SCTR (0.74) | SCTRSMOPDGFRABTKABL1 | |
| SCHEMBL14075698 | 0.84 | SCTR (0.72) | SCTRSMOKDM4EMEN1MAPT | |
| SCHEMBL14075700 | 0.83 | SCTR (0.76) | SCTRSMOBTKABL1PLK4 | |
| SCHEMBL14088204 | 0.81 | SCTR (0.71) | SCTRSMOKDM4EMEN1MAPT | |
| SCHEMBL14075696 | 0.79 | SCTR (0.98) | SCTRSMOPDGFRA | |
| SCHEMBL14075697 | 0.79 | SCTR (0.95) | SCTRSMOPDGFRA | |
| Purmorphamine SCHEMBL1548273 | 0.79 | SCTR (1.00) | SCTRSMOPDGFRA | |
| Purmorphamine SCHEMBL29358352 | 0.79 | SCTR (1.00) | SCTRSMOPDGFRA | |
| SCHEMBL31488323 | 0.76 | SCTR (0.63) | SCTRSMOKDM4EMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214541-A1 | COMPOSITIONS AND METHODS FOR INDUCING OSTEOGENESIS | IRM LLC (BM) | 2008-09-04 | — | — | US | disclosed |
| US-20080214541-A1 | COMPOSITIONS AND METHODS FOR INDUCING OSTEOGENESIS | IRM LLC (BM) | 2008-09-04 | — | — | US | disclosed |
| US-7273864-B2 | Compositions and methods for inducing osteogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-09-25 | — | — | US | disclosed |
| US-7273864-B2 | Compositions and methods for inducing osteogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214541-A1 | COMPOSITIONS AND METHODS FOR INDUCING OSTEOGENESIS | BMP2, BMP4, BMP6 | SCTR 3728/4885SMO 226/4885PDGFRA 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.